Tesetaxel: Additional Phase IIb data

Additional data from an open-label, U.S. Phase IIb trial in 24 evaluable patients showed that oral tesetaxel every 21 days produced an ORR of 50%, including 1 complete response and 11 partial responses. Additionally, 6 of the 12 responders cleared >75% of their measurable disease. The DCR was 83%. The trial has enrolled 33 women who may be hormone-refractory, but were previously untreated with chemotherapy for locally advanced or metastatic HER2-negative breast cancer. Data were presented at the San Antonio Breast Cancer Symposium. ...